The DoxyPEP Study evaluated the efficacy of doxycycline taken as post-exposure prophylaxis (PEP) on incidence of bacterial sexually transmitted infections (STIs), chlamydia (CT), gonorrhea (GC), and syphilis, in men who have sex with men (MSM) and transgender women (TGW).1 It was based on the earlie...
The FDA recently granted approval to lenacapavir (LEN), a novel long-acting HIV antiretroviral (ARV) that is classified as a capsid inhibitor. Lenacapavir is marketed in the United States as Sunlenca.
Lenacapavir blocks HIV-1’s assembly of its protein capsid and interferes with other steps in HIV rep...
The FDA recently approved the use of an extended-release injectable formulation of the integrase inhibitor cabotegravir (CAB) for preexposure prophylaxis (PrEP) for adults and adolescents at risk for HIV infection. After two initial intramuscular (IM) injections given 1 month apart, it is administer...
In December 2021, the U.S. Centers for Disease Control and Prevention issued thoroughly revised and updated PrEP guidelines. The guidelines include important new information on the use of oral PrEP (TDF/FTC and TAF/FTC) and recommendations on the use of injectable cabotegravir (CAB) as PrEP.
Key upda...
